← Back to headlines
AbbVie Gains EU Approval for Atogepant in Acute Migraine Treatment
AbbVie has received EU approval for atogepant, a treatment for acute migraine, expanding its therapeutic offerings in the European market.
2 Jun, 10:54 — 2 Jun, 10:54
Sources
Showing 1 of 1 sources
Related Stories
US Declares Strait of Hormuz Mine-Free Amid Ongoing Regional Diplomatic Efforts
20m ago
Global Markets Await Clarity on Interest Rates From Fed Chair at Jackson Hole
23m ago
Strabag Raises Annual Forecast Amid Record Construction Orders
23m ago
Venezuela Considers Leaving OPEC to Strengthen Ties With United States
33m ago